Mucosal immune cell priming by intranasally delivered Haemophilus haemolyticus is associated with heterologous protection against influenza and nontypeable Haemophilus influenzae
Frontiers in Immunology · 20.07.2026 · 17
DOI: 10.3389/fimmu.2026.1855464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 20.07.2026. Verfasst von Jack S Pepper und 14 weiteren Autor:innen. Beteiligte Einrichtung: Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Perth, WA, Australia. Hauptthemen laut MEDLINE: Haemophilus Infections, Haemophilus influenzae, Immunity, Mucosal, Influenza A virus. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Channel 7 Telethon Trust.
Abstract (Originalsprache)
Introduction
Intranasal vaccines offer a needle-free strategy to enhance immunity to respiratory infections. We investigated the mechanism of action of a novel intranasal vaccine using the human respiratory commensal Haemophilus haemolyticus (Hh), previously shown to protect against nontypeable Haemophilus influenzae (NTHi) otitis media and accelerate clearance of influenza A virus (IAV).
Methods
Mucosal and systemic cellular immune responses were assessed 2–144 hours after intranasal Hh treatment in mice, compared with placebo or the Toll-Like Receptor (TLR)2–6 agonist Pam2CSK4 using spectral flow cytometry. The impact of treatment on subsequent IAV and NTHi challenge was also evaluated.
Results
Hh induced a distinct, tissue-specific immune signature with rapid recruitment of neutrophils and inflammatory monocytes to the lungs, peaking at 6 hours, earlier than Pam2CSK4. Hh also generated higher proportions of nasal CD103 + CD4 + T cells within 48 hours, which further expanded following sequential IAV and NTHi infection.
Discussion
These findings demonstrate that Hh primes mucosal immune responses to promote heterologous protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Perth, WA, Australia.
- Centre for Child Health Research, The University of Western Australia, Perth, WA, Australia.
- Biostatistics, The Kids Research Institute Australia, Perth, WA, Australia.
- School of Biomedical Sciences, The University of Western Australia, Perth, WA, Australia.
- Medical, Molecular and Forensic Sciences, Murdoch University, Perth, WA, Australia.
- Wal-yan Respiratory Research Centre, The Kids Research Institute Australia, Perth, WA, Australia.
Förderung
- Channel 7 Telethon Trust
Zitieren
APA
Pepper, J. S., Granland, C. M., Clark, S. L., Thornton, R. B., Bayliss, J., Foo, M. Z. E., Billingham, W., Scott, N., Fulurija, A., Strickland, D. H., Wiertsema, S. P., Richmond, P. C., Seppanen, E. J., Kirkham, L. S., & Tjiam, M. C. (2026). Mucosal immune cell priming by intranasally delivered Haemophilus haemolyticus is associated with heterologous protection against influenza and nontypeable Haemophilus influenzae. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1855464
Vancouver
Pepper JS, Granland CM, Clark SL, Thornton RB, Bayliss J, Foo MZE, et al. Mucosal immune cell priming by intranasally delivered Haemophilus haemolyticus is associated with heterologous protection against influenza and nontypeable Haemophilus influenzae. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1855464
BibTeX
@article{Pepper2026,
author = {Pepper, Jack S and Granland, Caitlyn M and Clark, Sharon L and Thornton, Ruth B and Bayliss, Josephine and Foo, M Z Edison and Billingham, Wesley and Scott, Naomi and Fulurija, Alma and Strickland, Deborah H and Wiertsema, Selma P and Richmond, Peter C and Seppanen, Elke J and Kirkham, Lea-Ann S and Tjiam, M Christian},
title = {Mucosal immune cell priming by intranasally delivered Haemophilus haemolyticus is associated with heterologous protection against influenza and nontypeable Haemophilus influenzae},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1855464}
}
EUVIMED